Aurinia Pharmaceuticals Inc (AUPH)

[Cosa]

$4.9 million expected (article link below). To hit this number they would need over 300 patients signed on. During the 1st quarter they said they had a little over 250 patient applicants.

Here is the math for you guys.
300 patients x $65,000 (Estimated per year cost of drug) = $19,500,000
$19,500,000/4 (Divide by 4 for each quarter) = $4,875,000
$4,875,000 would be the quarterly revenue with 300 patients.

Lupus nephritis is considered an Orphan disease, with around 80,000 – 100,000 patients in U.S, and 1 million worldwide.

If we could get 10% or 8,000 patients, this would be $520,000,000 annual revenue. I think this is possible with A2 data safety results. It may take 3-5 years to get here. But this would be trading over $30 by then.

AUPH! I'm buying the dips.

https://www.marketbeat.com/instant-alerts/nasdaq-auph-consensus-analyst-rating-2021-07/